GoodGirlRx is not affiliated with, endorsed by, or sponsored by Novo Nordisk and does not manufacture this medication
The FLOW study highlights the risks of CKD progression, cardiovascular disease and death in those with type 2 diabetes and CKD, and the significant benefits of the pillars of treatment: ACE inhibitors/ARBs, SGLT2 inhibitors, finerenone and, now, semaglutide
So rather than forcing an increase, it supports the bodys natural process.
For many patients, it is the safest and most comfortable way to transition forward
If a patient isnt truly engaged or committed its different than someone in a different disease area